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ABSTRACT 
 
The postmenopausal osteoporosis of a 66-year-old female with long lasting end stage complex 
regional pain syndrome on the right hand was treated with strontium ranelate 2 grams daily. After 
few weeks of treatment an impressive improvement of pain and immobility of the right hand 
occurred. 
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1. CASE REPORT 
 
CRPS (complex regional pain syndrome), also 
referred to as reflex sympathetic dystrophy 
(RSD), Sudeck’s atrophy or algodystrophy, is a 
common chronic painful condition with allodynia, 
hyperalgesia, trophic changes and motor 
dysfunction of a limb, which often leads to a long-
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term disability. No evidence-based treatment is 
known [1]. Since CRPS is associated with bone 
demineralization, which results in patchy or 
diffuse osteoporosis, several studies in recent 
years have investigated the effect of 
bisphosphonates for CRPS, showing limited 
evidence for improvement of motor function, 
reduction of pain and an increase in local bone 
mineral density [2,3,4,5,6]. No satisfactory 
therapy for CRPS is yet known. 
 
We here present a 66-year-old female, who was 
first time seen at the Rheumatology Unit in 
February 2013. A decreased bone mass density 
was described some months earlier and calcium 
intake was recommended for treatment of her 
postmenopausal osteoporosis. She was unable 
to use her right hand because of stiffness and 
immobility in the metacarpo- and proximal 
interphalangeal joints. She also suffered from 
pain in the right hand. Blood tests showed 
normal values for blood cell count, erythrocyte 
sedimentation rate (ESR) and C-reactive protein 
(CRP). Bone turnover markers like calcium, 
phosphate, procollagen (P1NP) and beta-
crosslaps (beta-CTX) were normal; alkaline 
phosphatase and intact PTH were in the upper 
normal range. Sudeck’s atrophy was diagnosed 
in 1995 after distal radius fracture. Several 
therapeutic interventions including physical 
therapy and calcitonin injections were attempted 
without success. Chronic pain remained and 
immobility was rapidly progressing. 
 
The calcium supplementation for treatment                    
of the postmenopausal osteoporosis was 
recommended by her general practitioner but 
only sometimes taken by the patient.  
 
We decided to change the therapy of her 
postmenopausal osteoporosis. With respect                 
to her CRPS we did not recommend 
bisphosphonates. The patient agreed and gave 
her informed consent. 
 
Strontium ranelate 2 grams administered daily 
orally was started immediately [7]. Fingertip-hand 
distance, SF-SACRAH [8] and a visual analogue 
scale (VAS) of 100 mm (0=no pain) were used to 
document disease activity. 
 
Six weeks after the initial intake of strontium 
ranelate first improvements were reported 
already. At one of the following visits in 
September 2014 the fingertip-hand distance was 
1 mm (70 mm at the beginning) and the right 
hand could again be used for easy work. 
According to the clinical improvement since 
February 2013, SF-SACRAH decreased from 6.2 
to 1.8 and VAS from 80 to 9 mm (Fig. 1). The 
treatment effect on CRPS symptoms were a 
welcome and impressive side effect. 
 
CRPS is difficult to treat and often results in 
major disability and pain. Our patient suffered 
from CRPS for several years with constant                
pain and immobility until beginning our new 
 
 
Fig. 1. SF-SACRAH before and during therapy with strontium ranelate in a patient with  
long-standing CRPS 
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treatment. With strontium ranelate we observed 
an impressive improvement in joint motion, 
increased functionality and reduced pain. We 
suppose that the effect is based on strontium 
ranelate’s dual mechanism of action, namely 
promoting bone formation and decreasing              
bone resorption. Since there is no established 
treatment for CRPS, we suggest that            
strontium ranelate might be an effective 
therapeutic option. 
 
2. CONCLUSION 
 
Up to now no evidence based and successful 
therapy for CRPS is known. This case makes 
hope that strontium ranelate 2 g daily could be 
an effective therapeutic option. 
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